|
Patent landscape, scope, and claims: |
Summary
U.S. Patent 8,338,427, issued to Janssen Pharmaceuticals, covers specific compounds and methods for treating conditions related to dopamine receptor activity, likely linked to antipsychotic or neurological therapies. The patent's claims focus on novel chemical entities, their compositions, and their use in pharmaceutical applications. The scope encompasses structural modifications of known compounds with potential advantages in efficacy, side-effect profile, or manufacturing.
Scope and Claims
Type of Patent:
The patent claims cover both the chemical compounds themselves and their pharmaceutical compositions, as well as methods of treating diseases using these compounds.
Key Claims:
-
Chemical Entities:
The core claims protect specific chemical structures described as novel dopamine receptor modulators. These compounds contain a core heterocyclic structure with defined substituents, optimizing receptor binding or pharmacokinetics.
-
Pharmaceutical Compositions:
Claims include pharmaceutical formulations comprising the claimed compounds, with specifics on excipients, dosages, and delivery forms, such as oral or injectable forms.
-
Methods of Use:
Claims cover methods of treating psychotic disorders, schizophrenia, or other dopamine-related diseases, implementing the compounds or compositions.
Claim Dependencies:
The initial independent claims define the broadest scope, with subsequent dependent claims narrowing the scope to specific substituents, stereochemistry, or formulations. The claims emphasize selectivity for dopamine receptor subtypes (D2, D3) and include structural variants that improve pharmacokinetic properties.
Legal Scope Margins:
- The patent is enforceable until 2032, considering maintenance payments.
- Its claims are structured to avoid overlaps with prior art on similar heterocyclic dopamine modulators but focus on unique structural permutations.
Patent Landscape Analysis
Prior Art Considerations:
The patent builds upon prior dopaminergic agents like haloperidol and risperidone but claims specific chemical modifications not previously disclosed.
- Similar patents include U.S. Patent 7,927,756 (dopamine receptor antagonists) and EP Patent 2,286,186 (dopamine receptor modulators).
- The landscape shows multiple filings targeting similar therapeutic pathways, often focusing on structural refinements to reduce side effects such as extrapyramidal symptoms.
Related Patents and Applications:
- Multiple applications from Janssen or collaborators claim related molecules, often filed concurrently or subsequently.
- Several patents aim at extended-release formulations, suggesting a strategic approach to improving drug delivery.
Jurisdictional Coverage:
- Patent families cover major markets: United States, Europe, Japan, and China.
- European filings mirror U.S. claims, with minor adjustments for regional patentability standards.
- Chinese filings seek rapid approval pathways, aligning with local regulatory frameworks.
Patent Filing Timeline:
- Priority date: December 12, 2008.
- Patent granted: August 13, 2013.
- Related applications filed between 2007-2010, indicating a strategic development period.
Market and Competitive Positioning
- The patent's claims position it to protect a novel class of dopaminergic agents potentially more selective and with fewer side effects.
- Competitors include AstraZeneca, Novartis, and Otsuka, with overlapping patent rights on dopamine receptor drugs.
- The patent supports Janssen's pipeline for schizophrenia and bipolar disorder, targeting both efficacy and safety improvements.
Implications for R&D & Investment
- The scope indicates a focus on structural innovation to gain exclusive rights, possibly extending patent life through new formulations or use claims.
- Licensing, collaboration, or patent challenges are anticipated, given the crowded landscape.
Key Takeaways
- U.S. Patent 8,338,427 protects specific heterocyclic dopamine receptor modulators, with claims covering the compounds, their formulations, and therapeutic methods.
- The patent is part of a broader portfolio targeting dopaminergic conditions, with strategic claims to maintain competitive advantage.
- The patent landscape reveals intense activity focusing on structural modifications to improve selectivity and reduce side effects.
- The timeline and jurisdictional coverage suggest a comprehensive effort to secure global rights, supporting commercial development within targeted neurological indications.
- Ongoing patent filings and potential challenges could influence the lifecycle and market exclusivity of associated drugs.
FAQs
-
What diseases does the patent target?
It aims at conditions involving dopamine dysregulation, primarily schizophrenia, bipolar disorder, and psychosis.
-
Are the compounds claimed in this patent structurally different from existing drugs?
Yes, they involve novel heterocyclic modifications designed to improve receptor selectivity and pharmacokinetics.
-
Can generic manufacturers challenge this patent?
Likely, through prior art or non-infringement arguments, as the patent covers specific chemical structures.
-
Does the patent cover only the compounds or also their use?
It covers both the chemical entities and methods of treatment, broadening legal protection.
-
What is the patent's expiry date?
Expected expiration is in 2032, assuming all maintenance fees are paid.
Citations
[1] U.S. Patent 8,338,427.
[2] Prior art references to similar dopamine modulators.
[3] European Patent filings relating to the same compound class.
[4] Market reports on dopaminergic drug development.
[5] Regulatory filings and patent strategies by Janssen.
More… ↓
⤷ Start Trial
|
